Having trouble accessing articles? Reset your cache.

BL-1020: Phase II/III discontinued

BioLineRx discontinued the double-blind, international Phase II/III CLARITY trial after a pre-planned interim analysis of 168 evaluable patients experiencing an acute exacerbation of schizophrenia showed that oral BL-1020 would not meet the primary endpoint of improving cognition from baseline

Read the full 395 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers